Results 121 to 130 of about 265 (150)

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-4. Toxicity of metabolites of miocamycin: acute toxicity of Mb2 in mice.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites. At previous study, LD0 values of Mb1 were estimated more than 5,000 mg/kg in male and female mice. The object of this study was to evaluate acute toxicity in male and female mice after single oral administration of Mb2, a metabolite of MOM, at a dose level of 5 ...
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, T, Itoh, T, Koeda   +6 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-9. Toxicity of metabolites of miocamycin: subacute toxicity of Mb6 in rats.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. It is also known that LD50 values of Mb6 were 4,150 mg/kg in male mice and 4,000 mg/kg in female mice but LD0 values in male and female rats were estimated more than 5,000 mg/kg.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, T, Niizato, H, Kawaoto, H, Watanabe, N, Ishiwatari, H, Hayasaka, T, Koeda   +9 more
openaire   +1 more source

Miocamycin

Drugs & Therapy Perspectives, 1994
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-6. Toxicity of metabolites of miocamycin: subacute toxicity of Mb2 in rats.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. At previous study, the acute and subacute toxicity of Mb1 and acute toxicity of Mb2 were performed that those metabolites did not exhibit any lethal toxicity even at the maximum physically applicable dose.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, T, Niizato, H, Kawaoto, H, Watanabe, N, Ishiwatari, H, Hayasaka, T, Koeda   +9 more
openaire   +1 more source

Some pharmacokinetic data on miocamycin II. Concentrations in gynaecological tissues.

Drugs under experimental and clinical research, 1991
The gynaecological tissue levels of miocamycin were studied in ten female patients after pre-operative administration. The patients were divided into two groups on the basis of the scheduled sampling time. All the patients received 4200 mg of the drug, divided in 7 tablets of 600 mg each every 8 h, last administration 2 or 3 h before surgery.
P M, Furneri, A, Cianci, A, Garozzo, L, Roccasalva, M R, Pinizzotto, G, Palumbo, G, Tempera   +6 more
openaire   +1 more source

Comparison of Miocamycin versus Amoxycillin in Lower Respiratory Tract Infections in Children. Clinical Response and Effect on Natural Killer Activity

Journal of International Medical Research, 1988
Carlo Agostoni, Francesco Scaglione
exaly  

Miocamycin: effective in respiratory tract infections

InPharma, 1985
openaire   +1 more source

High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998

Journal of Antimicrobial Chemotherapy, 2000
Juan-Ignacio Alós, Carmen Torres
exaly  

[Miocamycin in ambulatory dental surgical practice].

Giornale di stomatologia e di ortognatodonzia, 1987
P, Capuzzi, F, Mazzanti, G, Balla, P, Tani   +3 more
openaire   +1 more source

Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis

Clinical Microbiology and Infection, 2003
BÜlent Bozdogan
exaly